HT
RLAY icon

Headlands Technologies’s Relay Therapeutics RLAY Stock Holding History

Headlands Technologies’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Sell
22,073
-25,553
-54% -$371K 0.04% 456
2026
Q1 		$474K Buy
+47,626
New +$426K 0.05% 373
2024
Q4 		– Sell
-74
Closed -$524 – 1520
2024
Q3 		$524 Buy
+74
New +$553 ﹤0.01% 1124

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Headlands Technologies's RLAY Position: Q2 2026 in Review

Headlands Technologies reduced its Relay Therapeutics (RLAY) stake by 54% in Q2 2026, selling an estimated $371K and leaving 22,073 shares worth $413K. The position accounts for 0.04% of the portfolio, ranked #456.

Headlands Technologies first reported a position in RLAY in Q3 2024 and has held it in 3 quarters since. The position peaked at $474K in Q1 2026. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Headlands Technologies held 22,073 shares of Relay Therapeutics worth $413K as of Q2 2026.
  • Headlands Technologies sold 25,553 Relay Therapeutics shares in Q2 2026, an estimated $371K.
  • Relay Therapeutics made up 0.04% of Headlands Technologies's portfolio in Q2 2026, its #456 holding.
  • Headlands Technologies first reported a position in Relay Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Headlands Technologies's Relay Therapeutics position peaked at $474K in Q1 2026.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.